In vivo imaging of siRNA delivery and silencing in tumors

Nature Medicine

Volumn 13, Issue 3, 2007, Pages 372-377

  Medarova, Zdravka ^a   Pham, Wellington ^a   Farrar, Christian ^a   Petkova, Victoria ^b   Moore, Anna ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ASPARTATE AMINOTRANSFERASE; DYE; INTERLEUKIN 6; IODINE 125; NANOPARTICLE; NEURONAL APOPTOSIS INHIBITORY PROTEIN; POLYARGININE; PROTEIN BIRC5; RED FLUORESCENT PROTEIN; SMALL INTERFERING RNA; SURVIVIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GENE THERAPY; CHEMICAL MODIFICATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; COVALENT BOND; CYTOKINE RELEASE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG LABELING; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; FEASIBILITY STUDY; GENE PROBE; GENE SILENCING; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMAGE QUALITY; IN VIVO STUDY; INTRACELLULAR SPACE; LIVER TOXICITY; MAGNETISM; MEMBRANE; MOLECULAR MODEL; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TREATMENT DURATION; TUMOR; TUMOR MODEL;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE SILENCING; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MOLECULAR PROBES; RNA, SMALL INTERFERING; SPECTROSCOPY, NEAR-INFRARED;

EID: 33847720312     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1486     Document Type: Article

References (35)

1. Bertrand, J.R. et al. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296, 1000-1004 (2002).
2. Brummelkamp, T.R., Bernards, R. & Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247 (2002).
3. Xia, H. et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816-820 (2004).
4. Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347-351 (2003).
5. Lewis, D.L., Hagstrom, J.E., Loomis, A.G., Wolff, J.A. & Herweijer, H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32, 107-108 (2002).
6. Layzer, J.M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766-771 (2004).
7. Hassani, Z. et al. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. 7, 198-207 (2005).
8. Landen, C.N., Jr. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
9. Takeshita, F. et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. USA 102, 12177-12180 (2005).
10. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005).
11. Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F. & Aigner, A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12, 461-466 (2005).
12. Dorn, G. et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49 (2004).
13. Hamar, P. et al. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 101, 14883-14888 (2004).
14. Bitko, V., Musiyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11, 50-55 (2005).
15. McCaffrey, A.P. et al. RNA interference in adult mice. Nature 418, 38-39 (2002).
16. Yano, J. et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10, 7721-7726 (2004).
17. Chiu, Y.L., Ali, A., Chu, C.Y., Cao, H. & Rana, T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 11, 1165-1175 (2004).
18. Moore, A., Medarova, Z., Potthast, A. & Dai, G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 64, 1821-1827 (2004).
19. Moore, A., Marecos, E., Bogdanov, A., Jr. & Weissleder, R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214, 568-574 (2000).
20. Bourrinet, P. et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest. Radiol. 41, 313-324 (2006).
21. Hu-Lieskovan, S., Heidel, J.D., Bartlett, D.W., Davis, M.E. & Triche, T.J. Sequencespecific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992 (2005).
22. Morrissey, D.V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007 (2005).
23. Judge, A.D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462 (2005).
24. Hornung, V. et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270 (2005).
25. Zaffaroni, N., Pennati, M. & Daidone, M.G. Survivin as a target for new anticancer interventions. J. Cell. Mol. Med. 9, 360-372 (2005).
26. Massoud, T.F. & Gambhir, S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17, 545-580 (2003).
27. Maeda, H., Fang, J., Inutsuka, T. & Kitamoto, Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3, 319-328 (2003).
28. Zimmer, C. et al. Tumor cell endocytosis imaging facilitates delineation of the gliomabrain interface. Exp. Neurol. 143, 61-69 (1997).
29. Harborth, J. et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13, 83-105 (2003).
30. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
31. Zimmermann, T.S. et al. RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114 (2006).
32. Tiscornia, G., Singer, O., Ikawa, M. & Verma, I.M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. USA 100, 1844-1848 (2003).
33. Tiscornia, G., Tergaonkar, V., Galimi, F. & Verma, I.M. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc. Natl. Acad. Sci. USA 101, 7347-7351 (2004).
34. Haas, J., Park, E.C. & Seed, B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6, 315-324 (1996).
35. Moore, A., Marecos, E., Simonova, M., Weissleder, R. & Bogdanov, A., Jr. Novel gliosarcoma cell line expressing green fluorescent protein: a model for quantitative assessment of angiogenesis. Microvasc. Res. 56, 145-153 (1998).